Coronavirus: Vaccines and Other Therapeutics
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".
Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 78470
Special Issue Editor
Interests: protein folding and design; protein dynamics and docking; macromolecular interaction and evolution; bio-therapeutics; intrinsically disordered proteins; membrane proteins and their drugging; criticality and phase transition; bio-energetics; graph theory and networks
Special Issue Information
Dear Colleagues,
As is well known to the community, the major focus of our journal, Vaccines (ISSN 2076-393X) is on laboratory and clinical vaccine research, utilization, and immunization. The Special Issue on “Coronavirus Vaccines and Other Therapeutics” focuses on high-quality research in any basic and/or applied area related to the ongoing coronavirus pandemic. We welcome articles (high-quality reviews, regular research papers, communications, and case reports) contributing either fundamentally or clinically to the concerted effort worldwide to combat the ongoing coronavirus pandemic. In addition to works on the standard vaccination approach, we are also encouraging studies on other therapeutic endeavors, e.g., other modes of immunization, antigen arrest, as well as novel inhibitors. We are also interested in computational approaches, especially those based on direct experimental data, and would appreciate works combining computation and experiments.
Dr. Sankar Basu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Immunization and Vaccines
- Inhibitors and Biotherapeutics
- Antigen Arrests
- SARS-CoV-2 and related Coronavirus strains
- Spike Protein
- Spike RBD – ACE-2 interaction
- Aerosols and viral transmission
- Immune response to coronavirus infection
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.